PROCEPT BioRobotics Corporation (PRCT)
NASDAQ: PRCT · IEX Real-Time Price · USD
68.10
-0.04 (-0.06%)
At close: May 17, 2024, 4:00 PM
67.49
-0.61 (-0.90%)
After-hours: May 17, 2024, 6:49 PM EDT
Company Description
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.
The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH.
PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
PROCEPT BioRobotics Corporation
Country | United States |
Founded | 2009 |
IPO Date | Sep 15, 2021 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 626 |
CEO | Dr. Reza Zadno Ph.D. |
Contact Details
Address: 150 Baytech Drive San Jose, California 95134 United States | |
Phone | (650) 232-9832 |
Website | procept-biorobotics.com |
Stock Details
Ticker Symbol | PRCT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $25.00 |
CIK Code | 0001588978 |
CUSIP Number | 74276L105 |
ISIN Number | US74276L1052 |
Employer ID | 26-0199180 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Reza Zadno Ph.D. | President, Chief Executive Officer and Director |
Kevin Waters | Executive Vice President and Chief Financial Officer |
Alaleh Nouri | EVice President, Chief Legal Officer and Corporate Secretary |
Hisham Shiblaq | Executive Vice President and Chief Commercial Officer |
Mohan F. Sancheti | Senior Vice President of Operations |
Barry Templin | Executive Vice President of Technology and Clinical Development |
Matthew James Bacso C.F.A. | Vice President of Investor Relations |
Stacey L. Porter | Chief People Officer |
Bijesh Chandran | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 3, 2024 | 144 | Filing |
May 3, 2024 | 8-K | Current Report |
May 2, 2024 | 10-Q | Quarterly Report |
May 1, 2024 | 144 | Filing |
May 1, 2024 | 8-K | Current Report |
Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 19, 2024 | 8-K | Current Report |
Mar 4, 2024 | 144 | Filing |